类风湿关节炎患者接受托法替布与肿瘤坏死因子抑制剂治疗的感染比较:开放标签随机对照ORAL Surveillance试验结果
ORAL Surveillance试验纳入年龄≥50岁且至少有一项心血管危险因素的类风湿关节炎患者,随机接受托法替布5或10 mg每日两次或TNFi。托法替布组所有感染、严重感染事件(SIE)和非严重感染(NSI)的发生率与风险比均高于TNFi组,10 mg高于5 mg;10 mg组SIE风险在≥65岁患者中更明显。SIE预测因素包括年龄增长、基线阿片类使用、慢性肺病史和口服糖皮质激素使用。
要点
- 托法替布10 mg每日两次组SIE的HR为1.48(95%CI 1.17至1.87),高于TNFi组。
- 托法替布5 mg每日两次组SIE的HR为1.17(95%CI 0.92至1.50),未达统计学显著。
- 托法替布10 mg组SIE风险在≥65岁患者中较50-<65岁更明显。
核心结论
- 托法替布组感染发生率高于TNFi组,研究结果可能为未来治疗决策提供参考。
研究设计与样本
- 开放标签随机对照试验ORAL Surveillance(NCT02092467),纳入年龄≥50岁且至少有一项额外心血管危险因素的类风湿关节炎患者,接受托法替布5或10 mg每日两次或TNFi。
主要发现
- 托法替布5和10 mg每日两次组所有感染、SIE和NSI的发生率与HR均高于TNFi组,10 mg高于5 mg。
- SIE的HR(95%CI)托法替布5 mg组为1.17(0.92至1.50),10 mg组为1.48(1.17至1.87),均与TNFi比较。
- 托法替布10 mg每日两次组所有感染和SIE的IRs/HRs升高在≥65岁患者中较50-<65岁更明显。
- SIE概率在托法替布5 mg组自第18个月起、10 mg组第6个月前较TNFi组增加;NSI概率在两种托法替布剂量组第6个月前较TNFi组增加。
- SIE最具预测性的风险因素为年龄增长、基线阿片类使用、慢性肺病史和时间依赖性口服糖皮质激素使用;NSI为女性、慢性肺病/感染史、既往吸烟和时间依赖性DAS28-CRP。
关键数值与推荐
- SIE的HR(95%CI)托法替布5 mg每日两次 vs TNFi为1.17(0.92至1.50),10 mg每日两次 vs TNFi为1.48(1.17至1.87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. METHODS: In this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour necrosis factor inhibitor (TNFi). Incidence rates (IRs; patients with first events/100 patient-years) and hazard ratios (HRs) were calculated for infections, overall and by age (50-<65 years; ≥65 years). Probabilities of infections were obtained (Kaplan-Meier estimates). Cox modelling identified infection risk factors. RESULTS: IRs/HRs for all infections, serious infection events (SIEs) and non-serious infections (NSIs) were higher with tofacitinib (10>5 mg two times per day) versus TNFi. For SIEs, HR (95% CI) for tofacitinib 5 and 10 mg two times per day versus TNFi, respectively, were 1.17 (0.92 to 1.50) and 1.48 (1.17 to 1.87). Increased IRs/HRs for all infections and SIEs with tofacitinib 10 mg two times per day versus TNFi were more pronounced in patients aged≥65 vs 50-<65 years. SIE probability increased from month 18 and before month 6 with tofacitinib 5 and 10 mg two times per day versus TNFi, respectively. NSI probability increased before month 6 with both tofacitinib doses versus TNFi. Across treatments, the most predictive risk factors for SIEs were increasing age, baseline opioid use, history of chronic lung disease and time-dependent oral corticosteroid use, and, for NSIs, female sex, history of chronic lung disease/infections, past smoking and time-dependent Disease Activity Score in 28 joints, C-reactive protein. CONCLUSIONS: Infections were higher with tofacitinib versus TNFi. Findings may inform future treatment decisions. TRIAL REGISTRATION NUMBER: NCT02092467.
引用
- Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022. PMID: 35922124. doi:10.1136/ard-2022-222405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。